Apr-17-24 08:19PM
|
|
Apr-16-24 09:53AM
|
|
Apr-11-24 02:21AM
|
|
Apr-10-24 11:03PM
|
|
Apr-08-24 06:31AM
|
|
06:28AM |
Loading… |
06:28AM
|
|
05:55AM
|
|
Apr-05-24 11:08PM
|
|
Mar-28-24 01:15PM
|
|
Mar-11-24 12:44PM
|
|
Mar-09-24 01:00PM
|
|
Mar-08-24 07:11AM
|
|
Mar-07-24 10:41AM
|
|
10:31AM
|
|
08:00AM
|
|
10:50AM |
Loading… |
Feb-27-24 10:50AM
|
|
Feb-14-24 04:43PM
|
|
Feb-13-24 12:32AM
|
|
Feb-10-24 09:53AM
|
|
Feb-09-24 11:28AM
|
|
09:30AM
|
|
09:13AM
|
|
08:37AM
|
|
08:14AM
|
|
08:11AM
|
(Associated Press Finance) |
08:03AM
|
|
07:59AM
|
|
Feb-08-24 06:37AM
|
|
05:48AM
|
|
04:53AM
|
|
12:55PM |
Loading… |
Feb-07-24 12:55PM
|
|
12:23PM
|
|
11:53AM
|
|
07:51AM
|
|
Feb-06-24 05:23PM
|
|
02:44PM
|
|
12:22PM
|
(The Wall Street Journal) |
11:13AM
|
|
09:47AM
|
|
08:37AM
|
|
06:19AM
|
|
Feb-05-24 06:35PM
|
(Morningstar Research) +9.74% |
06:25PM
|
|
06:07PM
|
|
04:35PM
|
(Investor's Business Daily) |
04:32PM
|
|
02:41PM
|
|
02:03PM
|
|
01:46PM
|
(Investor's Business Daily) |
01:21PM
|
|
01:04PM
|
(The Wall Street Journal) |
12:38PM
|
(The Wall Street Journal) |
12:27PM
|
|
12:13PM
|
|
11:04AM
|
|
10:57AM
|
|
10:36AM
|
|
10:35AM
|
|
10:29AM
|
|
10:26AM
|
|
09:03AM
|
|
07:59AM
|
|
07:40AM
|
|
06:56AM
|
(The Wall Street Journal) |
06:47AM
|
|
06:19AM
|
|
06:18AM
|
|
06:16AM
|
|
06:07AM
|
|
06:04AM
|
|
06:00AM
|
|
Jan-31-24 05:55AM
|
|
05:24AM
|
|
05:03AM
|
|
04:40AM
|
|
Jan-26-24 01:35PM
|
|
Jan-25-24 12:00PM
|
|
Jan-23-24 08:15AM
|
|
Jan-16-24 08:17AM
|
(Investor's Business Daily) |
Jan-04-24 08:44AM
|
|
Dec-19-23 04:15PM
|
|
Dec-15-23 11:30AM
|
|
10:17AM
|
|
08:40AM
|
|
Dec-14-23 06:40PM
|
|
Nov-17-23 07:50PM
|
|
Nov-16-23 12:31PM
|
|
09:30AM
|
|
09:29AM
|
|
08:58AM
|
|
08:29AM
|
|
08:12AM
|
|
12:55AM
|
(Thomson Reuters StreetEvents) |
Nov-15-23 05:25PM
|
|
04:58PM
|
|
04:23PM
|
|
01:00PM
|
|
12:11PM
|
|
08:49AM
|
|
07:49AM
|
|
|
|
|
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Gunther Scott | SVP, Quality & Reg. Affairs | Mar 15 '24 | Sale | 56.20 | 387 | 21,749 | 29,506 | Mar 19 01:38 PM | Ryan Michelle R | Director | Aug 31 '23 | Buy | 49.98 | 1,000 | 49,980 | 1,979 | Sep 05 06:00 PM | GREISCH JOHN J | Executive Chair | Aug 30 '23 | Buy | 50.24 | 21,000 | 1,055,040 | 34,000 | Sep 01 01:52 PM | Maselli Alessandro | President & CEO | Aug 24 '23 | Sale | 44.54 | 2,071 | 92,245 | 88,004 | Aug 25 07:16 PM | Fasman Steven L | EVP & Chief Admin Officer | Aug 24 '23 | Sale | 44.65 | 817 | 36,479 | 73,789 | Aug 25 07:02 PM | Gennadios Aristippos | Group Pres. Pharma & Consumer | Aug 24 '23 | Sale | 44.49 | 396 | 17,618 | 96,552 | Aug 25 07:05 PM | Grippo Michael J | SVP, Strategy & Corp. Dev. | Aug 24 '23 | Sale | 44.50 | 390 | 17,355 | 24,449 | Aug 25 07:08 PM | Pravda Ricardo | Chief Transformation Officer | Aug 24 '23 | Sale | 44.47 | 379 | 16,854 | 30,224 | Aug 25 06:37 PM | Hopson Ricky | Pres. Clinical Dev Supply Div | Aug 24 '23 | Sale | 44.56 | 276 | 12,299 | 22,040 | Aug 25 06:52 PM | Gunther Scott | SVP, Quality & Reg. Affairs | Aug 24 '23 | Sale | 44.57 | 269 | 11,989 | 29,932 | Aug 25 07:12 PM | Carletti Lorenzo | SVP Global Ops Ph & Cons Hlth | Aug 24 '23 | Sale | 44.71 | 216 | 9,657 | 8,746 | Aug 25 06:58 PM | Lickfold Charles | SVP, CIO | Aug 24 '23 | Sale | 44.72 | 190 | 8,497 | 11,339 | Aug 25 06:45 PM | Hawkeswood Thomas W | Pres. Pharma Prod Delivery Div | Aug 24 '23 | Sale | 44.72 | 147 | 6,574 | 7,533 | Aug 25 06:48 PM | Hunt Patricia | Pres. Consumer Health Div | Aug 24 '23 | Sale | 44.77 | 106 | 4,746 | 11,289 | Aug 25 06:39 PM | Arnold Jonathan | SVP, CCO & Div. Head BioP Del. | Aug 24 '23 | Sale | 44.87 | 87 | 3,904 | 57,399 | Aug 25 06:56 PM | Fasman Steven L | EVP & Chief Admin Officer | Aug 01 '23 | Sale | 47.05 | 1,637 | 77,026 | 60,216 | Aug 03 04:02 PM | Maselli Alessandro | President & CEO | Aug 01 '23 | Sale | 47.13 | 1,485 | 69,995 | 86,101 | Aug 03 05:05 PM | Carletti Lorenzo | SVP Global Ops Ph & Cons Hlth | Aug 01 '23 | Sale | 47.77 | 383 | 18,296 | 4,602 | Aug 03 04:16 PM | Gennadios Aristippos | Group Pres. Pharma & Consumer | Aug 01 '23 | Sale | 47.59 | 281 | 13,373 | 86,488 | Aug 03 04:21 PM | Grippo Michael J | SVP, Strategy & Corp. Dev. | Aug 01 '23 | Sale | 47.72 | 276 | 13,171 | 17,516 | Aug 03 04:30 PM | Pravda Ricardo | Chief Transformation Officer | Aug 01 '23 | Sale | 47.56 | 269 | 12,793 | 19,739 | Aug 03 05:13 PM | Hawkeswood Thomas W | Pres. Pharma Prod Delivery Div | Aug 01 '23 | Sale | 47.97 | 258 | 12,376 | 5,106 | Aug 03 04:41 PM | Hopson Ricky | Pres. Clinical Dev Supply Div | Aug 01 '23 | Sale | 47.86 | 195 | 9,333 | 16,257 | Aug 03 04:47 PM | Gunther Scott | SVP, Quality & Reg. Affairs | Aug 01 '23 | Sale | 47.90 | 190 | 9,101 | 23,798 | Aug 03 04:37 PM | Hunt Patricia | Pres. Consumer Health Div | Aug 01 '23 | Sale | 47.95 | 161 | 7,720 | 9,154 | Aug 03 04:51 PM | Lickfold Charles | SVP, CIO | Aug 01 '23 | Sale | 47.90 | 135 | 6,466 | 5,570 | Aug 03 05:00 PM | Arnold Jonathan | SVP, CCO & Div. Head BioP Del. | Aug 01 '23 | Sale | 47.80 | 62 | 2,964 | 55,896 | Aug 03 04:09 PM | Boerman Manja | Pres. BioModalities Division | May 01 '23 | Sale | 49.86 | 1,446 | 72,098 | 14,414 | May 03 07:00 PM | Gargiulo Mario | SVP, Ops, Biologics Europe | May 01 '23 | Sale | 49.86 | 678 | 33,805 | 5,676 | May 03 06:58 PM |
|